Concepts in Immunology and Immunotherapeutics, 4th Edition provides a wide-ranging introduction to both basic and applied immunology.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.

This book highlights information derived primarily from clinical samples, with particular reference to theoretical and scientific aspects of the human immune system. This text will focus on topics that range from host-pathogen interactions in infectious disease to host immune response in cancer, allergic diseases, neuroinflammatory diseases, and autoimmune disorders. The reader will also have a well-rounded understanding of the behavior of the immune system with particular emphasis on the role of immunoproteomics in immunotherapy, neuroprotective immunity for neurodegenerative and neuroinfectious disease, leukemia-associated dendritic cell induction of adaptive immunity dysregulation, and the role of immune checkpoint inhibitors in cancer, infection, as well as neuroinflammation. Taken together, the contents of this book are intended for both clinicians and researchers in academia and industry.

The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

Introductory Immunology quickly acquaints readers with natural immune responses manifesting in diseases and disorders. The book presents a complete picture of natural defenses to infectious agents, as well as the mechanisms that lead to autoimmune dysfunction. In addition, it examines immunologically based diseases, giving the reader sufficient knowledge to make sound clinical decisions leading to better treatment outcomes. Introductory Immunology is aimed at researchers, postgraduates, or any scientifically inclined reader interested in immunology. No prior expertise in medical, biochemical, or cellular science is needed to benefit from the clear presentation of immunology concepts in this book. - Quick, concise introduction to immunological concepts - Breaks down all of immunology into manageable, logically digestible building blocks - Geared toward readers without medical, biochemical, or cellular expertise

Knapp und präzise erklärt dieses einführende Lehrbuch der Immunologie die Funktion des Immunsystems anhand sorgfältig ausgewählter Beispiele aus der klinischen Praxis und dem Experiment. Von Büchern mit ähnlichem Themenspektrum unterscheidet es sich durch den klar evidenzbasierten Ansatz. Die Autoren -- ein erfahrener Dozent und ein angesehener Forscher -- regen dabei stets zur kritischen Reflexion des gelernten Stoffs an. Based on examples using clinical and experimental data, this concise introductory textbook provides an insight into the immune system, prompting readers to ask critical questions in order to further advance our understanding. Website: www.wiley-vch.de/home/immunology

This textbook provides a unique support in gaining essential knowledge on the immune response, its diagnosis and its modification by drugs and chemicals. The first section of the book, covering a basic introduction to immunology and its relevance for human disease, has been updated to accommodate new immunological concepts. The second section on immunodiagnostics has been further expanded to describe widely used molecular techniques and is followed by a systematic coverage of drugs affecting the immune system, revised to cover recent developments. The book concludes with a chapter on immunotoxicology. This third edition continues the unique format dealing with four related topics in a single volume, obviating the need to refer to several different textbooks. New aids to the reader include a two-column format, glossaries of technical terms and appendix reference tables. The emphasis on illustrations is maintained from the first edition.

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.